Grand Medical Pty

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the completion of patient enrollment and dosing in its Phase II study for STC3141, a sepsis therapy developed by Grand Medical Pty Ltd, the company’s innovative drug R&D center in Australia. The preliminary results of the study are anticipated by…